To elucidate the basis for increased YAP/TAZ translocation in drug-resistant metastatic breast cancer LM2 cells, we performed multiplexed high-throughput genetic screens, systematically knocking down the majority of human RhoGEFs and RhoGAPs while simultaneously measuring YAP/TAZ nuclear localisation. The gene discussed is YAP1; the disease is breast carcinoma.